Trial Profile
An Open-label, Parallel-group Study to Determine the Single and Multiple Dose Pharmacokinetics of Elinogrel and Its Metabolite in Patients With Mild, Moderate, and Severe Renal Impairment Compared to Healthy Subjects.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Elinogrel (Primary) ; Aspirin
- Indications Embolism and thrombosis; Renal impairment
- Focus Pharmacokinetics
- 23 Nov 2010 Primary endpoints identified as reported by ClinicalTrials.gov.
- 23 Nov 2010 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 23 Sep 2010 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.